TB-500 vs Histatin-5

TB-500 and Histatin-5 are both research peptides studied across multiple applications, yet they diverge markedly in their biological origins and research focus. TB-500, a synthetic fragment of thymosin beta-4, is explored for wound healing and cardiac repair, with some human clinical trials supporting its safety and efficacy. In contrast, Histatin-5, an endogenous salivary peptide, is a key player in innate antifungal defense, particularly against Candida species. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.

TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found throughout human tissues. TB-500 contains the active healing region (sequence: Ac-LKKTETQ, MW ~889 g/mol) responsible for cell migration and tissue repair. It has a handful of human RCTs for wound healing and dry eye, plus a dedicated safety trial in 40 healthy adults showing minimal adverse effects. Despite this, it remains unapproved for human therapeutic use in all major markets and is banned by WADA and in horse racing.It contains the active healing region (sequence: Ac-LKKTETQ, molecular weight ~889 g/mol) responsible for cell migration and tissue repair. Research suggests TB-500 accelerates wound healing, reduces inflammation, and promotes cardiac repair in preclinical models. A handful of human randomized controlled trials have investigated its effects on wound healing and dry eye, including a dedicated safety trial in 40 healthy adults that reported minimal adverse effects. Despite this evidence, TB-500 remains unapproved for human therapeutic use in all major markets and is banned by the World Anti-Doping Agency and in horse racing.

Histatin-5 is a 24-amino-acid histidine-rich cationic peptide (sequence: DSHAKRHHGYKRKFHEKHHSHRGY, molecular weight ~3036 g/mol) found in human saliva. It is the most potent antifungal member of the histatin family, which comprises at least 12 peptides secreted by parotid and submandibular salivary glands. Studies indicate Histatin-5 exerts a unique non-lytic killing mechanism against Candida albicans, targeting the fungal cell mitochondria rather than disrupting the cell membrane. Reduced levels of Histatin-5 in saliva have been associated with increased susceptibility to oral candidiasis, highlighting its role in innate oral antifungal defense. Research continues to explore its potential in antimicrobial applications.

These peptides target distinct research areas with minimal overlap. TB-500 is primarily investigated in injury recovery and anti-inflammatory contexts, including wound healing, cardiac repair, and ocular surface restoration. Histatin-5, on the other hand, is focused on antimicrobial research and oral health, particularly against Candida species and other oral pathogens. Researchers should consider these divergent applications when designing studies, as the peptides' mechanisms and evidence bases support different experimental models.

TB-500: A safety-focused randomized controlled trial in 40 healthy adults (2010) was designed expressly to assess safety and found minimal adverse effects with synthetic thymosin beta-4. No significant safety concerns have been reported in published human studies to date. Common anecdotal side effects include injection site pain or redness, lightheadedness, mild headache, nausea, and fatigue. Histatin-5: As an endogenous component of normal human saliva, present at 15–30 micromolar in parotid saliva, Histatin-5 is naturally occurring. However, no exogenous therapeutic products exist for safety evaluation. Its activity is reduced by physiological salt concentrations and salivary mucins, which may influence experimental outcomes.